Copyright Reports & Markets. All rights reserved.

Global Valacyclovir Oral Market Insights, Forecast to 2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Valacyclovir Oral Industry
  • 1.7 COVID-19 Impact: Valacyclovir Oral Market Trends

    • 2 Global Valacyclovir Oral Quarterly Market Size Analysis

    • 2.1 Valacyclovir Oral Business Impact Assessment - COVID-19
      • 2.1.1 Global Valacyclovir Oral Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Valacyclovir Oral Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Valacyclovir Oral Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Valacyclovir Oral Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Valacyclovir Oral Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Valacyclovir Oral Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Valacyclovir Oral Market
    • 3.5 Key Manufacturers Valacyclovir Oral Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Valacyclovir Oral Segments, By Type

    • 4.1 Introduction
      • 1.4.1 500mg tablet
      • 1.4.2 1000mg tablet
      • 1.4.3 300mg tablet
      • 1.4.4 Others
    • 4.2 By Type, Global Valacyclovir Oral Market Size, 2019-2021
      • 4.2.1 By Type, Global Valacyclovir Oral Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Valacyclovir Oral Price, 2020-2021

    5 Impact of Covid-19 on Valacyclovir Oral Segments, By Application

    • 5.1 Overview
      • 5.5.1 Hospital
      • 5.5.2 Drug store
    • 5.2 By Application, Global Valacyclovir Oral Market Size, 2019-2021
      • 5.2.1 By Application, Global Valacyclovir Oral Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Valacyclovir Oral Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 GSK
      • 7.1.1 GSK Business Overview
      • 7.1.2 GSK Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.1.3 GSK Valacyclovir Oral Product Introduction
      • 7.1.4 GSK Response to COVID-19 and Related Developments
    • 7.2 Sandoz
      • 7.2.1 Sandoz Business Overview
      • 7.2.2 Sandoz Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.2.3 Sandoz Valacyclovir Oral Product Introduction
      • 7.2.4 Sandoz Response to COVID-19 and Related Developments
    • 7.3 Sun Pharmaceutical
      • 7.3.1 Sun Pharmaceutical Business Overview
      • 7.3.2 Sun Pharmaceutical Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.3.3 Sun Pharmaceutical Valacyclovir Oral Product Introduction
      • 7.3.4 Sun Pharmaceutical Response to COVID-19 and Related Developments
    • 7.4 Cipla
      • 7.4.1 Cipla Business Overview
      • 7.4.2 Cipla Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.4.3 Cipla Valacyclovir Oral Product Introduction
      • 7.4.4 Cipla Response to COVID-19 and Related Developments
    • 7.5 Mylan
      • 7.5.1 Mylan Business Overview
      • 7.5.2 Mylan Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.5.3 Mylan Valacyclovir Oral Product Introduction
      • 7.5.4 Mylan Response to COVID-19 and Related Developments
    • 7.6 Teva
      • 7.6.1 Teva Business Overview
      • 7.6.2 Teva Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.6.3 Teva Valacyclovir Oral Product Introduction
      • 7.6.4 Teva Response to COVID-19 and Related Developments
    • 7.7 Zydus Pharmaceuticals
      • 7.7.1 Zydus Pharmaceuticals Business Overview
      • 7.7.2 Zydus Pharmaceuticals Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.7.3 Zydus Pharmaceuticals Valacyclovir Oral Product Introduction
      • 7.7.4 Zydus Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.8 West-Ward Pharmaceuticals
      • 7.8.1 West-Ward Pharmaceuticals Business Overview
      • 7.8.2 West-Ward Pharmaceuticals Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.8.3 West-Ward Pharmaceuticals Valacyclovir Oral Product Introduction
      • 7.8.4 West-Ward Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.9 Time Cap Labs
      • 7.9.1 Time Cap Labs Business Overview
      • 7.9.2 Time Cap Labs Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.9.3 Time Cap Labs Valacyclovir Oral Product Introduction
      • 7.9.4 Time Cap Labs Response to COVID-19 and Related Developments
    • 7.10 Wockhardt
      • 7.10.1 Wockhardt Business Overview
      • 7.10.2 Wockhardt Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.10.3 Wockhardt Valacyclovir Oral Product Introduction
      • 7.10.4 Wockhardt Response to COVID-19 and Related Developments
    • 7.11 Apotex
      • 7.11.1 Apotex Business Overview
      • 7.11.2 Apotex Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.11.3 Apotex Valacyclovir Oral Product Introduction
      • 7.11.4 Apotex Response to COVID-19 and Related Developments
    • 7.12 Aurobindo Pharma
      • 7.12.1 Aurobindo Pharma Business Overview
      • 7.12.2 Aurobindo Pharma Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.12.3 Aurobindo Pharma Valacyclovir Oral Product Introduction
      • 7.12.4 Aurobindo Pharma Response to COVID-19 and Related Developments
    • 7.13 Jubilant Pharma
      • 7.13.1 Jubilant Pharma Business Overview
      • 7.13.2 Jubilant Pharma Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.13.3 Jubilant Pharma Valacyclovir Oral Product Introduction
      • 7.13.4 Jubilant Pharma Response to COVID-19 and Related Developments
    • 7.14 Lunan Pharmaceutical
      • 7.14.1 Lunan Pharmaceutical Business Overview
      • 7.14.2 Lunan Pharmaceutical Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.14.3 Lunan Pharmaceutical Valacyclovir Oral Product Introduction
      • 7.14.4 Lunan Pharmaceutical Response to COVID-19 and Related Developments
    • 7.15 Shandong Luoxin Pharmaceutical Group
      • 7.15.1 Shandong Luoxin Pharmaceutical Group Business Overview
      • 7.15.2 Shandong Luoxin Pharmaceutical Group Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.15.3 Shandong Luoxin Pharmaceutical Group Valacyclovir Oral Product Introduction
      • 7.15.4 Shandong Luoxin Pharmaceutical Group Response to COVID-19 and Related Developments
    • 7.16 Tasly
      • 7.16.1 Tasly Business Overview
      • 7.16.2 Tasly Valacyclovir Oral Quarterly Production and Revenue, 2020
      • 7.16.3 Tasly Valacyclovir Oral Product Introduction
      • 7.16.4 Tasly Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Valacyclovir Oral Supply Chain Analysis
      • 8.1.1 Valacyclovir Oral Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Valacyclovir Oral Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Valacyclovir Oral Distribution Channels
      • 8.2.2 Covid-19 Impact on Valacyclovir Oral Distribution Channels
      • 8.2.3 Valacyclovir Oral Distributors
    • 8.3 Valacyclovir Oral Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Valacyclovir Oral, including the following market information:
      Global Valacyclovir Oral Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Valacyclovir Oral Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Valacyclovir Oral Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Valacyclovir Oral Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)

      Key market players
      Major competitors identified in this market include GSK, Sandoz, Sun Pharmaceutical, Cipla, Mylan, Teva, Zydus Pharmaceuticals, West-Ward Pharmaceuticals, Time Cap Labs, Wockhardt, Apotex, Aurobindo Pharma, Jubilant Pharma, Lunan Pharmaceutical, Shandong Luoxin Pharmaceutical Group, Tasly, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      500mg tablet
      1000mg tablet
      300mg tablet
      Others

      Based on the Application:
      Hospital
      Drug store

      Buy now